Boostability of One priming dose intramuscular Rabies vaccine especially in Senior age groups

Not Applicable

Completed

• Conditions: Rabies; Infection - Other infectious diseases

• Registration Number: ACTRN12619000946112
• Lead Sponsor: uis Furuya-Kanamori

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-07-05
• Study Completion: 2020-12-04
• Last Update Posted: 5 July 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 103

Inclusion Criteria

1. No prior history of rabies vaccination
2. Able to give written Informed Consent and sign consent after all aspects of the protocol have been explained
3. Subject must agree to participate in three doses of vaccine, three to four blood tests and two questionnaires including the planned follow-up telephone review

Exclusion Criteria

1. Taking medications that impair the normal functioning of the immune system
2. Pregnancy or planning pregnancy
3. Travelling to areas of high risk for rabies where an unusual pre-exposure prophylaxis schedule may cause difficulty in the event of an animal exposure that requires post-exposure prophylaxis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Antibodies titer levels to rabies virus (IU/mL) using serum assay (Platella Rabies II ELISA)[60 days post initial vaccination];Antibodies titer levels to rabies virus (IU/mL) using serum assay (Platella Rabies II ELISA)[67 days post initial vaccination]

Secondary Outcome Measures

Name	Time	Method
Self-reported side effects of the vaccination (e.g. injection site reactions [pain, swelling, itching, or redness], headache, dizziness, muscle pain, nausea, pain)[74 days post initial vaccination];Antibodies titer levels to rabies virus (IU/mL) using serum assay (Platella Rabies II ELISA)[81 days post initial vaccination]